Gsa Capital Partners LLP Lipocine Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$0.89 - $1.85 $391,984 - $814,799	-440,432 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.2 $123,872 - $150,148	125,124 Added 39.68%	440,432 $437,000
Q3 2021 Nov 12, 2021	BUY	$1.08 - $1.49 $187,689 - $258,942	173,787 Added 122.8%	315,308 $344,000
Q2 2021 Aug 05, 2021	BUY	$1.17 - $1.59 $18,167 - $24,689	15,528 Added 12.32%	141,521 $198,000
Q1 2021 May 10, 2021	SELL	$1.38 - $2.28 $82,798 - $136,797	-59,999 Reduced 32.26%	125,993 $190,000
Q4 2020 Feb 03, 2021	BUY	$1.2 - $1.69 $127,410 - $179,435	106,175 Added 133.02%	185,992 $253,000
Q3 2020 Nov 06, 2020	BUY	$1.21 - $2.23 $23,533 - $43,371	19,449 Added 32.22%	79,817 $113,000
Q2 2020 Aug 11, 2020	BUY	$0.42 - $1.26 $25,354 - $76,063	60,368 New	60,368 $76,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $463M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.